Becton Dickinson and Co (BDX) : Jensen Investment Management Inc reduced its stake in Becton Dickinson and Co by 0.92% during the most recent quarter end. The investment management company now holds a total of 2,263,481 shares of Becton Dickinson and Co which is valued at $395,045,339 after selling 21,116 shares in Becton Dickinson and Co , the firm said in a disclosure report filed with the SEC on Jul 26, 2016.Becton Dickinson and Co makes up approximately 5.97% of Jensen Investment Management Inc’s portfolio.
Other Hedge Funds, Including , Portland Global Advisors reduced its stake in BDX by selling 70 shares or 0.66% in the most recent quarter. The Hedge Fund company now holds 10,560 shares of BDX which is valued at $1,843,037. Becton Dickinson and Co makes up approx 0.82% of Portland Global Advisors’s portfolio.Huntington National Bank boosted its stake in BDX in the latest quarter, The investment management firm added 86,365 additional shares and now holds a total of 133,893 shares of Becton Dickinson and Co which is valued at $23,368,345. Becton Dickinson and Co makes up approx 0.57% of Huntington National Bank’s portfolio. Court Place Advisors added BDX to its portfolio by purchasing 1,182 company shares during the most recent quarter which is valued at $206,294. Becton Dickinson and Co makes up approx 0.12% of Court Place Advisors’s portfolio. Fox Run Management L.l.c. added BDX to its portfolio by purchasing 3,000 company shares during the most recent quarter which is valued at $527,340. Becton Dickinson and Co makes up approx 0.24% of Fox Run Management L.l.c.’s portfolio. Summit Financial Wealth Advisors sold out all of its stake in BDX during the most recent quarter. The investment firm sold 2,900 shares of BDX which is valued $509,356.
Becton Dickinson and Co opened for trading at $175.65 and hit $176.98 on the upside on Friday, eventually ending the session at $176, with a gain of 0.02% or 0.04 points. The heightened volatility saw the trading volume jump to 7,75,782 shares. Company has a market cap of $37,348 M.
On the company’s financial health, Becton Dickinson and Co reported $2.18 EPS for the quarter, beating the analyst consensus estimate by $ 0.17 according to the earnings call on May 5, 2016. Analyst had a consensus of $2.01. The company had revenue of $3067.00 million for the quarter, compared to analysts expectations of $3073.41 million. The company’s revenue was up 49.5% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.61 EPS.
Many Wall Street Analysts have commented on Becton Dickinson and Co. Company shares were Reiterated by RBC Capital Mkts on May 9, 2016 to “Sector Perform”, Firm has raised the Price Target to $ 169 from a previous price target of $153 .
Becton Dickinson and Company is a global medical technology company engaged in the development manufacture and sale of a range of medical supplies devices laboratory equipment and diagnostic products used by healthcare institutions life science researchers clinical laboratories pharmaceutical industry and the general public. The Company operates through two segments: BD Medical and BD Life Sciences. The Company’s Life Sciences segment consists of the BD Diagnostics and BD Biosciences segments. The Company’s BD Medical segment focuses on providing solutions to reduce the spread of infection enhance diabetes treatment and advance drug delivery. The Company’s BD Diagnostics provides products for the safe collection and transport of diagnostics specimens as well as instruments and reagent systems. Its BD Biosciences provide diagnostic and research tools to life science researchers clinical researchers laboratory professionals and clinicians.